Skip to main content

Table 7 Summary of results of ability to detect change of NVSA© scores with the sPGA and effect size

From: Development and psychometric validation of the Nausea/Vomiting Symptom Assessment patient-reported outcome (PRO) instrument for adults with secondary hyperparathyroidism

 

No change

Any worsening

Any improvement

 

Number of days of vomiting or Nausea

Number of vomiting episodes

Mean severity of Nausea

Number of days of vomiting or Nausea

Number of vomiting episodes

Mean severity of Nausea

Number of days of vomiting or Nausea

Number of vomiting Episodes

Mean severity of Nausea

Difference in Means

 Range

−0.13 – 0.19

− 0.15 – 0.51

− 0.12 – 0.21

− 0.05 – 1.83

− 0.99 – 2.40

− 0.22 – 0.76

− 1.80 – 0.17

−3.77 – − 1.07

−1.02 – − 0.21

 Mean

0.02

0.06

0.00

0.65

1.21

0.32

− 0.88

−2.14

0.49

 Median

0.00

0.07

0.04

0.55

0.21

0.45

−1.05

−1.37

−0.29

Within-Patient Effect Size

 Range

0.00–0.08

0.00–0.29

0.01–0.17

0.02–0.78

0.26–1.37

0.06–0.73

0.07–0.73

0.60–0.97

0.22–0.82

 Mean

0.04

0.12

0.06

0.28

0.88

0.36

0.38

0.83

0.40

 Median

0.04

0.07

0.04

0.23

0.60

0.38

0.42

0.88

0.29

  1. The within-patient effect size was defined as the within-patient change score (post-pre score) divided by pre (group) standard deviation